Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P39 vs Xolair PK/Safety in Healthy Subjects
NCT04018313Phase 1Completed
- Sponsor
- Celltrion
- Start
- May 2020
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CT-P39 in allergic asthma, chronic spontaneous urticaria (CSU), chronic rhinosinusitis with nasal polyps (CRSwNP) and 1 more (5 arms), sponsored by Celltrion. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Infinity, Area Under the Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration and 1 more. Started May 2020; status: completed.
02
Drugs
CT-P39
03
Conditions
allergic asthmachronic spontaneous urticaria (CSU)chronic rhinosinusitis with nasal polyps (CRSwNP)food allergy
Beyond the preview
Go deeper on NCT04018313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04018313.